<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04236635</url>
  </required_header>
  <id_info>
    <org_study_id>EN3835-213</org_study_id>
    <nct_id>NCT04236635</nct_id>
  </id_info>
  <brief_title>Histopathology Following CCH Injection</brief_title>
  <official_title>A Phase 2B, Open-Label Study to Explore Tissue Histopathology Following Subcutaneous Injection of Collagenase Clostridium Histolyticum Using An Abdominoplasty Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the histopathology of subcutaneous tissue isolated after single or multiple&#xD;
      Collagenase Clostridium Histolyticum (CCH) injection techniques in adult female subjects&#xD;
      undergoing abdominoplasty.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 20, 2019</start_date>
  <completion_date type="Actual">October 26, 2020</completion_date>
  <primary_completion_date type="Actual">September 23, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histopathology before and after CCH treatment compared to control tissue (tissue not administered with CCH)</measure>
    <time_frame>Approximately 3 months</time_frame>
    <description>Histopathology of removed tissue defined by the observation and analysis of the removed specimen by a trained Pathologist</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Characteristics of Subcutaneous Tissue</condition>
  <arm_group>
    <arm_group_label>Single CCH Subcutaneous Injection Technique</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 0.07mg EN3835 (Collagenase Clostridium Histolyticum) in each injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple CCH Subcutaneous Injection Technique</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 0.07mg EN3835 (Collagenase Clostridium Histolyticum) in each injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EN3835</intervention_name>
    <description>Collagenase Clostridium Histolyticum (CCH)</description>
    <arm_group_label>Multiple CCH Subcutaneous Injection Technique</arm_group_label>
    <arm_group_label>Single CCH Subcutaneous Injection Technique</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be adequately informed and understand the nature and risks of the study and be able to&#xD;
             provide consent.&#xD;
&#xD;
          2. Be undergoing planned elective abdominoplasty.&#xD;
&#xD;
          3. Be willing to have their tissue donated for evaluation.&#xD;
&#xD;
          4. Be judged to be in good health.&#xD;
&#xD;
          5. Have a negative pregnancy test.&#xD;
&#xD;
          6. Be willing and able to cooperate with the requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is from a vulnerable population, as defined by the US Code of Federal Regulations&#xD;
             (CFR) Title 45, Part 46, Section 46.111(b) and other local and national regulations,&#xD;
             including but not limited to, employees (temporary, part-time, full time, etc) or a&#xD;
             family member of the research staff conducting the study, or of the sponsor, or of the&#xD;
             contract research organization, or of the Institutional Review Board (IRB)/Independent&#xD;
             Ethics Committee (IEC).&#xD;
&#xD;
          2. Has systemic conditions (coagulation disorders, malignancy, keloidal scar, abnormal&#xD;
             wound healing) that restricts study participation.&#xD;
&#xD;
          3. Has local (in the areas to be treated) conditions (thrombosis, vascular disorder,&#xD;
             active infection/inflammation, active cutaneous alteration, tattoo/mole) that&#xD;
             restricts study participation.&#xD;
&#xD;
          4. Required use of anticoagulant or antiplatelet medication (except â‰¤ 150 mg aspirin&#xD;
             daily) before or during participation in the trial.&#xD;
&#xD;
          5. Past history of any abdominal surgery, including but not limited to: liposuction,&#xD;
             caesarean section, appendectomy, cholecystectomy, or umbilical hernia repair.&#xD;
&#xD;
          6. Has used or intends to use any local applications/therapies/injections/procedures that&#xD;
             restricts study participation.&#xD;
&#xD;
          7. Is presently nursing or providing breast milk in any manner.&#xD;
&#xD;
          8. Intends to become pregnant during the study.&#xD;
&#xD;
          9. Intends to initiate an intensive sport or exercise program regimen during the study.&#xD;
&#xD;
         10. Intends to use any tanning spray or tanning booths during the study.&#xD;
&#xD;
         11. Has received any investigational drug or treatment within 30 days prior to first&#xD;
             injection of study drug.&#xD;
&#xD;
         12. Has a known systemic allergy to collagenase or any other excipient of study drug.&#xD;
&#xD;
         13. Has received any collagenase treatment at any time prior to treatment in this study.&#xD;
&#xD;
         14. Any other condition(s) that, in the investigator's opinion, might indicate the subject&#xD;
             to be unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Chajko</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #1</name>
      <address>
        <city>Montclair</city>
        <state>New Jersey</state>
        <zip>07042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #2</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <pending_results>
    <submitted>September 23, 2021</submitted>
    <returned>October 22, 2021</returned>
    <submitted>November 16, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

